Mike Deustar, President and CEO of Novo Nordisk, dives into the groundbreaking launch of their oral GLP-1 pill, addressing its cardiovascular benefits and pricing strategies. Jeff Marthin, CEO of Medtronic, shares insights on innovative FDA-approved devices like the smart glucose pen and the company's ambitious diabetes spin-off plans. Albert Borla, Chairman of Pfizer, explores their weight-loss initiatives and acquisition strategies amid looming loss of exclusivity. Finally, Brent Saunders, CEO of Bausch & Lomb, reveals exciting advancements in eye care and a robust growth plan.
